Alpelisib: First Global Approval
2019-07-03T03:42:42Z (GMT) by
Compliance with Ethical Standards
Disclosure The preparation of this review was not supported by any external funding.
Conflicts of interest A. Markham, a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Insight Report can be found here
Alpelisib (Piqray™) - an orally available phosphatidylinositol 3-kinase (PI3K) inhibitor with specific activity against PI3K alpha (PI3Kα) - is being developed by Novartis for the treatment of breast cancer. Alpelisib has demonstrated efficacy in combination with fulvestrant as treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer in patients with a PIK3CA mutation and was recently approved for this indication in the USA. This article summarizes the milestones in the development of alpelisib leading to this first approval.
© Springer Nature Switzerland AG 2019